Back to Trials
NCT06953349Recruiting

Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis

Barnet Dulaney Perkins Eye Centers

Start Date

3/31/2025

Completion Date

12/31/2025

Summary

Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis

Detailed Description

The use of combination Phacoemulsification, OMNI Canaloplasty and Hydrus microstent successfully lowers IOP in ethnically-diverse patients with Open Angle Glaucoma

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Subjects with h/o CEIOL/OMNI/Hydrus (chosen based on subjects on more than 1 medication pre-operatively) with at least 3 years of follow up data * have Glaucoma Exclusion Criteria: * Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies. * Patients with refractory CME or CME persisting 3 months or more post-operatively * Patients with incomplete IOP, medication logs or VF data within post-operative period * Prior incisional surgery or MIGS

Interventions

PROCEDURE

Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Open-Angle Glaucoma

Locations

Barnet Dulaney Perkins Eye Center

Mesa, Arizona 85206

United States